Bio-Research.AI

#𝐏𝐟𝐢𝐳𝐞𝐫 𝐀𝐥𝐥𝐨𝐬𝐭𝐞𝐫𝐢𝐜 𝐁𝐢𝐧𝐝𝐞𝐫 𝐃𝐞𝐚𝐥 [Deals] 01/03 Eton Pharmaceuticals acquires Galzin® for Wilson disease and will commercialize in the U.S. with European supply as Wilzin® with advice from Stifel 01/02 Radius Pharmaceuticals Ltd grants Pharmanovia exclusive rights to commercialize abaloparatide in Asia Pacific regions same day : ( ↓ NASDAQ: RDUS | -2.04% ) 01/02 Atavistik Bio and Pfizer collaborate to discover novel precision allosteric therapeutics using AMPS platform with option for licensing after research period same day : ( ↑ NYSE: PFE | +0.3% ) [Venture Capital] 01/03 GenKOre secures 10 billion KRW bridge investment from InterVest and receives preferential listing benefits for its gene editing technology [Regulatory] 01/03 Innovent Biologics announces China's NMPA approval of second NDA for DOVBLERON to treat adult patients with locally advanced or metastatic ROS1-positive NSCLC 01/03 GSK's mepolizumab approved by China NMPA as add-on therapy for adults with chronic rhinosinusitis with nasal polyps following phase III MERIT trial same day : ( ↓ LSE: GSK | -0.44% ) 01/02 Capricor Therapeutics, Inc. completes BLA submission for deramiocel to treat Duchenne muscular dystrophy cardiomyopathy backed by phase 2 HOPE-2 trial data same day : ( ↑ NASDAQ: CAPR | +8.41% ) View the full newsletter contents for free via the link in the comments.

#𝐓𝐡𝐫𝐞𝐞 𝐍𝐞𝐰 𝐘𝐞𝐚𝐫 𝐃𝐞𝐚𝐥𝐬-𝐃𝐋𝐋3 𝐀𝐃𝐂, 𝐌𝐲𝐨𝐬𝐭𝐚𝐭𝐢𝐧 𝐀𝐛, 𝐎𝐩𝐢𝐨𝐢𝐝 𝐛𝐥𝐨𝐜𝐤𝐞𝐫 #𝐤 𝐎𝐩𝐢𝐨𝐢𝐝 𝐛𝐥𝐨𝐜𝐤𝐞𝐫 𝐅𝐚𝐢𝐥 𝐢𝐧 𝐃𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐏𝐡3 [Clinical Trials] 01/02 Neumora Therapeutics' phase 3 KOASTAL-1 study shows navacaprant does not significantly improve depressive symptoms compared to placebo but notes efficacy signal in female participants 01/02 Zhaoke Ophthalmology's phase III trial of TAB014 for wet age-related macular degeneration meets primary and key secondary endpoints, showing improved visual acuity at week 52 compared to Lucentis [Deals] 01/02 Sino Biopharmaceuticals’ subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. secures exclusive eleven-year agreement with Ping An-Shionogi to market Shionogi's Naldemedine in China to benefit patients with opioid-induced constipation 01/02 iBio, Inc. in-licenses anti-myostatin antibody IBIO-600 from AstralBio, plans bispecific antibody program for obesity and cardiometabolic disorders by 2026 01/01 Innovent Biologics Grants Roche Exclusive Rights to IBI3009 for $80M Upfront, Potential $1B in Milestones in Small Cell Lung Cancer Deal [Regulatory] 01/02 SIGA Technologies' antiviral treatment TEPOXX approved in Japan for smallpox mpox cowpox and post-smallpox vaccination complications 01/01 Shanghai MicuRx Pharmaceuticals's anti-infection drug MRX-5 granted orphan drug designation by US FDA for treatment of non-tuberculous mycobacteria infections View the full newsletter contents for free via the link in the comments.

#𝐑𝐎𝐂𝐊 1/2 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐡𝐚𝐥𝐭𝐞𝐝 #𝐇𝐚𝐩𝐩𝐲 𝐍𝐞𝐰 𝐘𝐞𝐚𝐫 [Clinical Trials] 12/31 Valo Health's phase 2 SPECTRA Study Fails Primary and Secondary Objectives, Company Suspends Development of OPL-0401 for Diabetic Retinopathy 12/31 Xgene Pharmaceutical's phase 2b Study of XG005 Reveals Significant Pain Intensity Reduction in Bunionectomy Patients [Deals] 12/31 Galera Therapeutics, Inc. acquires Nova Pharmaceuticals in a $3M deal backed by Ikarian Capital LLC and aims to finance future clinical trials until 2026 View the full newsletter contents for free via the link in the comments.

𝐓𝐡𝐞 𝐘𝐞𝐚𝐫 𝟐𝟎𝟐𝟒 𝐂𝐥𝐨𝐬𝐞𝐬 𝐰𝐢𝐭𝐡 #𝐋𝐨𝐧𝐠-𝐋𝐚𝐬𝐭𝐢𝐧𝐠 𝐆𝐋𝐏-𝟏𝐑 𝐀𝐧𝐭𝐚𝐠𝐨𝐧𝐢𝐬𝐭 𝐃𝐞𝐚𝐥 #𝐂𝐡𝐢𝐧𝐚 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡'𝐬 𝐏𝐫𝐞-𝐀 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 [Clinical Trials] 12/30 Axsome Therapeutics, Inc.' ACCORD-2 Trial of AXS-05 Shows Delay in Alzheimer's Disease Agitation Relapse, ADVANCE-2 Study Results Non-Significant same day : ( ↓ NASDAQ: AXSM | -2.21% ) [Deals] 12/31 Brii Biosciences Acquires BRII-179 Intellectual Property from VBI Vaccines Inc. for $18M, Cancels Future Payment Obligations 12/30 Pfizer Ends Global Agreement on Hemophilia A Gene Therapy Product, Sangamo Therapeutics, Inc. to Retake Control by April 2025 same day : ( ↓ NASDAQ: SGMO | -8.59% ) ( ↓ NYSE: PFE | -0.75% ) 12/30 Lupin Acquires Huminsulin from Eli Lilly and Company in India, Bolstering its Diabetes Care Portfolio same day : ( ↓ NYSE: LLY | -1.19% ) 12/30 Orion and Marinus Pharma End European Distribution Deal for Epilepsy Drug, Ganaxolone same day : ( ↑ NASDAQ: MRNS | +41.78% ) 12/30 Radiopharm Theranostics and Lantheus forge $2M co-development deal for oncology radiopharmaceuticals in Australia same day : ( ↓ NASDAQ: LNTH | -3.19% ) 12/30 Gubra Teams up with Amylyx Pharmaceuticals for a $50M Deal to Develop Potential Novel Long-lasting GLP-1 Receptor Antagonist same day : ( ↓ NASDAQ: AMLX | -0.78% ) [Venture Capital] 12/31 Orange Sail Pharmaceuticals secures $50 million in Pre-A financing for drug pipeline development in oncology and autoimmune diseases [Regulatory] 12/30 Chimerix, Inc. submits dordaviprone application to FDA for recurrent diffuse glioma treatment same day : ( ↓ NASDAQ: CMRX | -0.58% ) 12/30 European Commission approves RYBREVANT and LAZCLUZE combo for first-line treatment of advanced NSCLC with EGFR mutations following MARIPOSA study results View the full newsletter contents for free via the link in the comments.

📊 2024 𝐓𝐨𝐩 10 𝐏𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐕𝐂 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬 💰 #1𝐁𝐢𝐥 𝐔𝐒𝐃 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀? #𝐎𝐧𝐠𝐨𝐢𝐧𝐠 𝐨𝐩𝐭𝐢𝐦𝐢𝐬𝐦 𝐀𝐈-𝐛𝐚𝐬𝐞𝐝 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 #𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐞𝐝𝐠𝐞 𝐆𝐋𝐏-1 In 2024, 𝐀𝐈 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦𝐬 and 𝐆𝐋𝐏-1 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 are driving trends in biopharma VC investments. 🚀 Compared to last year, the number of investments increased by 6.9%, and total funding grew by $5.8 billion, reflecting steady growth. (Source:Bio-Research.AI) Find out who secured the biggest investments! 1️⃣ Xaira Therapeutics (Series A: $1B) 🌟 Backed by $1 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 from ARCH Venture Partners, Foresite Capital, and others, Xaira aims to revolutionize drug discovery and develop innovative therapies using 𝐀𝐈. 2️⃣ Metsera (Series A: $290M + Series B: $215M) 🧬 Founded by ARCH Venture Partners and Population Health Partners, Metsera raised $505 million to develop 𝐆𝐋𝐏-1 𝐫𝐞𝐜𝐞𝐩𝐭𝐨𝐫 𝐚𝐠𝐨𝐧𝐢𝐬𝐭𝐬 and peptide-based treatments for obesity and metabolic diseases. 3️⃣ Mirador Therapeutics (Series A: $400M) 💡 Backed by $400 million from ARCH Venture Partners, OrbiMed, and others, Mirador utilizes its 𝐌𝐢𝐫𝐚𝐝𝐨𝐫360™ 𝐞𝐧𝐠𝐢𝐧𝐞 to develop precision medicines for immune-mediated inflammatory and fibrotic diseases. 3️⃣ Kailera Therapeutics (Series A: $400M) 💉 With $400 million from Atlas Venture, Bain Capital Life Sciences, and RTW Investments, Kailera is advancing 𝐆𝐋𝐏-1/𝐆𝐈𝐏 𝐝𝐮𝐚𝐥 𝐚𝐠𝐨𝐧𝐢𝐬𝐭𝐬 and therapies for obesity and related conditions. 🔍 Subscribe to Bio-Research.AI for the latest biopharma insights! ✨ Which technology or investment excites you the most? Share your thoughts in the comments! 💬 ARCH Venture Partners Foresite Capital Wellington Management VENROCK HEALTHCARE CAPITAL PARTNERS LP Atlas Venture Bain Capital RTW Investments, LP Formation Bio Andreessen Horowitz Candid Therapeutics Fairmount Funds Management LLC TCGX venBio Arsenal Biosciences, Inc. Regeneron Ventures Seaport Therapeutics Sofinnova Investments Uniquity Bio Blackstone Cardurion Pharmaceuticals Ascenta Capital

#𝐌𝐚𝐫𝐢𝐧𝐮𝐬' 𝐉𝐨𝐮𝐫𝐧𝐞𝐲 𝐄𝐧𝐝𝐬 𝐰𝐢𝐭𝐡 $151𝐌 #𝐂𝐡𝐢𝐧𝐚'𝐬 𝐃𝐋𝐋3 𝐀𝐃𝐂 𝐛𝐢𝐥𝐥𝐢𝐨𝐧-𝐝𝐨𝐥𝐥𝐚𝐫 𝐥𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 𝐝𝐞𝐚𝐥 [Clinical Trials] 12/30 CARsgen Therapeutics reports a significant improvement in PFS in phase II trial of satricabtagene autoleucel infusion for advanced gastric cancers 12/30 Intrathecal Gene Therapy OAV101 Shows Significant Improvements in HFMSE Scores in Phase III SMA Study [Deals] 12/30 Huadong Medicine Co., Ltd. and SynerK, Inc partner to develop hypertension drug SNK-2726, Huadong granted exclusive rights in Greater China 12/30 Immedica Pharma AB acquires Marinus Pharmaceuticals for $151M, gaining global rights to ZTALMY and leveraging expansion into North America 12/29 IDEAYA Biosciences Licenses DLL3-Targeting Antibody Drug SHR-4849 to Jiangsu Hengrui Pharmaceuticals in Deal Worth Up to $1.045B View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Venture Capital] 12/26 AusperBio secures USD 73 million in Series B funding round for phase 2 development of chronic hepatitis B therapy AHB-137 [Regulatory] 12/27 Takeda's HYQVIA gets approval in Japan for agammaglobulinemia and hypogammaglobulinemia 12/27 Japan approves supplemental application of VYVDURA in adults with CIDP based on ADHERE Study results 12/27 ONO PHARMACEUTICAL CO., LTD. gains supplemental approval for Opdivo in combined urothelial carcinoma treatment in Japan after successful phase 3 trial 12/27 TEVIMBRA, combined with chemotherapy, receives second FDA approval for advanced gastric and gastroesophageal junction cancers 12/27 Daiichi Sankyo's DATROWAY gains approval in Japan for specific breast cancer treatment following TROPION-Breast01 phase 3 trial results 12/27 Chugai Pharmaceutical Co., Ltd. gets supplementary approval for LUNSUMIO in treating relapsed follicular lymphoma after two previous therapies in Japan 12/27 Eli Lilly Japan obtain authorization for Zepbound in Japan for obesity treatment based on SURMOUNT-J study results 12/27 PDRadiopharma gets approval from Japan's Ministry for Tauvid and donanemab use in Alzheimer's disease patients 12/27 Nippon Shinyaku receives supplemental approval for Uptravi tablets in Japan for pediatric pulmonary arterial hypertension treatment View the full newsletter contents for free via the link in the comments.

#𝗦𝗧𝗔𝗧𝟲 𝗕𝗶𝗴 𝗽𝗵𝗮𝗿𝗺𝗮 𝗟𝗶𝗰𝗲𝗻𝘀𝗶𝗻𝗴 𝗱𝗲𝗮𝗹 𝗮𝗳𝘁𝗲𝗿 𝗖𝗵𝗿𝗶𝘀𝘁𝗺𝗮𝘀 #𝗚𝗗𝗡𝗙, 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗢𝗯𝗲𝘀𝗶𝘁𝘆 𝗧𝗮𝗿𝗴𝗲𝘁? [Clinical Trials] 12/26 Assembly Biosciences, Inc. Reports Significant Antiviral Activity in phase 1b Study of ABI-4334 for Chronic Hepatitis B [Deals] 12/26 Johnson & Johnson gains exclusive global license for Kaken Pharmaceutical Co Ltd's STAT6 program 12/26 Hoth Therapeutics, Inc acquires exclusive patent license from U.S. Department of Veterans Affairs and Emory University for innovative obesity treatment technology View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/25 Qilu Pharmaceuticals's phase I preliminary results demonstrates anti-tumor activity and tolerance of QLS32015 in patients with relapsed/refractory multiple myeloma [Deals] 12/24 Achilles Therapeutics plc Sells TRACERx NSCLC Study License and MAP to AstraZeneca for $12M, AstraZeneca to Sponsor MAP same day : ( ↓ NASDAQ: AZN | -0.5% ) ( ↑ NASDAQ: ACHL | +16.21% ) 12/24 Bio-Thera Solutions partners with Tabuk Pharmaceutical to commercialize BAT2206 in Saudi Arabia under Astra Industrial Group's subsidiary's exclusive distribution rights [Regulatory] 12/25 JCR Pharmaceuticals' JR-441 receives orphan drug designation from Japan's MHLW for mucopolysaccharidosis type IIIA treatment, following similar designations in Europe and US View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/24 TiumBio Co. concludes phase 1a clinical trial of hemophilia treatment TU7710 with high safety and prolonged half-life [Deals] 12/24 GlycoNex Inc. Licenses Denosumab Biosimilar SPD8 for Development, Regulatory Approval and Commercialization 12/24 Alfresa Group invests in KORTUC INC. for clinical trials of cancer radiosensitizer, securing exclusive negotiation rights for distribution in Japan 12/23 Ikena Oncology, Inmagene Biopharmaceuticals Merge for Development of IMG-007 with $75M Syndicated Private Placement, Raising $175M for Drug's Progress same day : ( ↑ NASDAQ: IKNA | +7.74% ) 12/23 60 Degrees Pharmaceuticals, INC and Tufts Medical Center partner to develop and commercialize tafenoquine for babesiosis treatment same day : ( ↓ NASDAQ: SXTP | -7.94% ) 12/23 Neutrolis Inc. signs exclusive licensing agreement with the University of Illinois Chicago for the development of dry eye disease treatment 12/23 CORXEL Pharmaceuticals acquires cardiometabolic drug CX11 from Vincentage, aims for global phase 2 trials in 2025 [Venture Capital] 12/23 GEMMA Biotherapeutics obtains $34 million in seed funding for gene therapy programs and growth support 12/23 Ubix Therapeutics, Inc. secures pre-IPO investment for clinical trials and pipeline expansion after beginning phase 1 B-cell lymphoma trials 12/23 Rznomics Inc. secures 20.3 billion KRW in pre-IPO funding, advances RNA editing research [Regulatory] 12/24 Daiichi Sankyo and AstraZeneca withdrawal EU application for datopotamab deruxtecan, continue development for lung cancer treatment 12/24 FDA Approves GEMTESA for Men with Overactive Bladder Symptoms Already Receiving Benign Prostatic Hyperplasia Therapy same day : ( ↓ JPX: 4506 | -0.53% ) 12/23 AstraZeneca's Tagrisso secures EU approval for treatment of non-small cell lung cancer based on LAURA phase III trial outcomes 12/23 FDA accepts Nuvation Bio's NDA for taletrectinib, sets target action date for June 2025 same day : ( ↓ NYSE: NUVB | -0.37% ) 12/23 EC approves Opdivo and Yervoy for first-line treatment of specific types of colorectal cancer based on CheckMate -8HW trial results same day : ( ↑ NYSE: BMY | +0.47% ) View the full newsletter contents for free via the link in the comments.